Ibutamoren (MK-677) Capsules

A small molecule, not a peptide

MK-677 came out of Merck's programme to convert the peptidic growth hormone-releasing peptides into orally available drug-like molecules. The resulting spiropiperidine scaffold retains agonist activity at GHS-R1a but has none of the amide backbone that makes peptides substrates for gastric and intestinal proteases. It is therefore absorbed intact, which is why it is the only orally administered secretagogue in common research use.

Sustained versus pulsatile signalling

What published work has examined

• Sleep architecture, where reported effects on slow-wave and REM sleep are consistent with ghrelin-receptor involvement in sleep regulation.
• Body composition, with reported increases in fat-free mass in older adult study populations.
• Bone turnover markers and bone mineral density endpoints in trials of extended duration.
• Appetite and food intake, an expected consequence of ghrelin-receptor agonism.
• Effects on fasting glucose and insulin sensitivity, which have been reported and are a recognised consideration in this class.

Regulatory and interpretive notes

Capsules require no reconstitution, which removes the sterility and stability handling that vialed peptides demand. Keep the bottle sealed at room temperature with its desiccant intact, away from direct light, heat and humid environments; capsule shells soften and can stick together if stored above ambient conditions. Do not transfer capsules into unlabelled containers — the lot number on the bottle is what ties the material to its certificate of analysis. Handle with standard laboratory precautions, log receipt and lot against your inventory records, and keep the product clearly marked for laboratory research use only, stored separately from any consumable items.